ESMO 2025 – Padcev plus Keytruda sets the perioperative bar
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
ASCO-GU – Corbus backs Chinese data with its own
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Innate shows Bicycle the path for Nectin-4
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
